Article
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Feb 2017
Lee S-H, Lee J-K, Ahn M-J, Kim D-W, Sun J-M, Keam B, Kim T M, Heo D S, Ahn J S, Choi Y-L, Min H-S, Jeon Y K, Park K
Abstract excerpt
Background: Chromosomal rearrangements involving RET, which are found in about 1% of non-small cell lung cancer (NSCLC), define a unique molecular subset. We performed this study to examine the efficacy and safety of vandetanib 300 mg daily in this patient population. Patients and methods: This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.